APOE and Alzheimer disease: A follow-up study in a transgenic mouse model of AD (3xTg) showed that treatment with D-APOJ(113–122) by intermittent intraperitoneal (i.p.)injections for 6 weeks reduced Aβ levels in the hippocampus and cortex to a similar extent as treatments with the dual-domain APOE mimetic peptide Ac-hE-18A-NH2 and the anti-Aβ antibody scFv-h3D6 [221].